A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Hoofdauteur: | |
|---|---|
| Andere auteurs: | |
| Formaat: | Project report |
| Taal: | English |
| Gepubliceerd in: |
Brac University
2024
|
| Onderwerpen: | |
| Online toegang: | http://hdl.handle.net/10361/23909 |
| id |
10361-23909 |
|---|---|
| record_format |
dspace |
| spelling |
10361-239092024-08-27T21:05:46Z A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab Chakraborty, Anupama Islam, Farzana School of Pharmacy, Brac University Metastatic Melanoma Combination therapy Ipilimumab Nivolumab Metastasis Melanoma Chemotherapy, Combination This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of the project report. Includes bibliographical references (pages 36-44). Chemotherapy, radiation therapy, surgery, and other treatments have proven to be ineffective for a patient suffering with metastatic melanoma. Recently, immunotherapy has become a potential method for treating the condition. Combination therapy, which focuses on various immune system components, has grabbed the attention of the scientific world. The treatment of metastatic melanoma with the immune checkpoint inhibitors Ipilimumab and Nivolumab has been demonstrated to be very successful. This review aims to analyze the current literature and articles from PubMed and Google Scholar and ClinicalTrials.gov on the use of Ipilimumab and Nivolumab in treating metastatic melanoma. Moreover, this work focuses at some clinical trial results for this combination therapy. The findings demonstrate that Ipilimumab and Nivolumab combination therapy substantially increases patient survival. In conclusion, Ipilimumab and Nivolumab in combination is a very promising treatment for metastatic melanoma. However, there are several clinical and practical issues that must be resolved to maximize the effectiveness of this combination therapy more research in the field is required. Anupama Chakraborty B. Pharmacy 2024-08-27T04:27:03Z 2024-08-27T04:27:03Z ©2023 2023-10 Project report ID 19346043 http://hdl.handle.net/10361/23909 en Brac University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 44 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Metastatic Melanoma Combination therapy Ipilimumab Nivolumab Metastasis Melanoma Chemotherapy, Combination |
| spellingShingle |
Metastatic Melanoma Combination therapy Ipilimumab Nivolumab Metastasis Melanoma Chemotherapy, Combination Chakraborty, Anupama A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab |
| description |
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Islam, Farzana |
| author_facet |
Islam, Farzana Chakraborty, Anupama |
| format |
Project report |
| author |
Chakraborty, Anupama |
| author_sort |
Chakraborty, Anupama |
| title |
A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab |
| title_short |
A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab |
| title_full |
A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab |
| title_fullStr |
A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab |
| title_full_unstemmed |
A review on Metastatic Melanoma combination therapy Ipilimumab-Nivolumab |
| title_sort |
review on metastatic melanoma combination therapy ipilimumab-nivolumab |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23909 |
| work_keys_str_mv |
AT chakrabortyanupama areviewonmetastaticmelanomacombinationtherapyipilimumabnivolumab AT chakrabortyanupama reviewonmetastaticmelanomacombinationtherapyipilimumabnivolumab |
| _version_ |
1814309735513456640 |